$500K
1 filing since 2025 · latest Equity filed
Zeo ScientifiX, Inc., formerly known as Organicell Regenerative Medicine, Inc., is a publicly traded, clinical-stage biopharmaceutical company. It focuses on researching, developing, and manufacturing biological therapeutics derived from perinatal sources to treat degenerative diseases and support regenerative medicine applications.
What sets it apart
The company's primary differentiator is its proprietary perinatal-sourced biologic technology platform, which is supported by ethical sourcing practices and rigorous batch testing protocols to ensure product quality and chain-of-custody ethics.
Zofin is the company's lead clinical candidate, an acellular biologic therapeutic formulated from perinatal sources. It is currently advancing through Phase I/II clinical trials for its potential to treat conditions such as COVID-19, chronic obstructive pulmonary disease (COPD), and knee osteoarthritis.
